S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
66,000% upside on tiny biotech? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
66,000% upside on tiny biotech? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
66,000% upside on tiny biotech? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
66,000% upside on tiny biotech? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:BNTX

BioNTech (BNTX) Stock Forecast, Price & News

$101.86
-1.26 (-1.22%)
(As of 09/26/2023 ET)
Compare
Today's Range
$101.09
$102.64
50-Day Range
$98.50
$125.08
52-Week Range
$95.50
$188.99
Volume
419,068 shs
Average Volume
683,853 shs
Market Capitalization
$24.55 billion
P/E Ratio
5.71
Dividend Yield
N/A
Price Target
$158.69

BioNTech MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
55.8% Upside
$158.69 Price Target
Short Interest
Healthy
1.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of BioNTech in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-64.05%
From $6.62 to $2.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

434th out of 964 stocks

Biological Products, Except Diagnostic Industry

61st out of 157 stocks


BNTX stock logo

About BioNTech (NASDAQ:BNTX) Stock

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BNTX Price History

BNTX Stock News Headlines

3 Stocks to Buy For the COVID Resurgence (BNTX)
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
BioNTech Unusual Options Activity For August 30
H.C. Wainwright Reaffirms Their Buy Rating on BioNTech SE (BNTX)
How to Play the Covid Vaccine Rally
See More Headlines
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

BNTX Company Calendar

Last Earnings
8/07/2023
Today
9/27/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNTX
Employees
4,530
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$158.69
High Stock Price Forecast
$260.00
Low Stock Price Forecast
$116.00
Forecasted Upside/Downside
+55.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

Net Income
$9.94 billion
Pretax Margin
62.27%

Debt

Sales & Book Value

Annual Sales
$18.24 billion
Cash Flow
$40.42 per share
Book Value
$87.07 per share

Miscellaneous

Free Float
194,720,000
Market Cap
$24.55 billion
Optionable
Not Optionable
Beta
0.17

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Prof. Ugur Sahin M.D. (Age 58)
    Co-Founder, CEO & Chair of the Management Board
    Comp: $479.34k
  • Dr. Ozlem Tureci M.D. (Age 56)
    Co-Founder, Chief Medical Officer & Member of Management Board
    Comp: $890.97k
  • Mr. Jens H. Holstein (Age 60)
    CFO & Member of Management Board
    Comp: $938.26k
  • Dr. Sierk Poetting Ph.D. (Age 50)
    MD, COO & Member of Management Board
    Comp: $985.54k
  • Mr. Ryan Richardson (Age 44)
    Chief Strategy Officer, MD & Member of Management Board
    Comp: $476.11k
  • Mr. Sean Marett (Age 58)
    Chief Bus. Officer, Chief Commercial Officer & Member of Management Board
    Comp: $913.54k
  • Dr. James Timothy Patrick Ryan Ph.D. (Age 48)
    Chief Legal Officer & Member of the Management Board
  • Sylke Maas Ph.D.
    VP of Investor Relations and Bus. Strategy
  • Michael Boehler
    MD & Head of Global External Communications
  • Dr. Oliver Hennig Ph.D.
    Sr. VP of Operations













BNTX Stock - Frequently Asked Questions

Should I buy or sell BioNTech stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BNTX shares.
View BNTX analyst ratings
or view top-rated stocks.

What is BioNTech's stock price forecast for 2023?

10 equities research analysts have issued 12-month price targets for BioNTech's stock. Their BNTX share price forecasts range from $116.00 to $260.00. On average, they expect the company's share price to reach $158.69 in the next year. This suggests a possible upside of 55.8% from the stock's current price.
View analysts price targets for BNTX
or view top-rated stocks among Wall Street analysts.

How have BNTX shares performed in 2023?

BioNTech's stock was trading at $150.22 at the start of the year. Since then, BNTX shares have decreased by 32.2% and is now trading at $101.86.
View the best growth stocks for 2023 here
.

When is BioNTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our BNTX earnings forecast
.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.04. The business earned $167.70 million during the quarter, compared to analyst estimates of $628.13 million. BioNTech had a net margin of 47.37% and a trailing twelve-month return on equity of 21.46%. BioNTech's quarterly revenue was down 94.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $7.31 earnings per share.

What is Ugur Sahin's approval rating as BioNTech's CEO?

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?

(BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

What is BioNTech's stock symbol?

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

Who are BioNTech's major shareholders?

BioNTech's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.09%), Temasek Holdings Private Ltd (1.88%), Flossbach Von Storch AG (1.43%), Artisan Partners Limited Partnership (0.84%), BlackRock Inc. (0.72%) and Capital World Investors (0.38%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioNTech's stock price today?

One share of BNTX stock can currently be purchased for approximately $101.86.

How much money does BioNTech make?

BioNTech (NASDAQ:BNTX) has a market capitalization of $24.55 billion and generates $18.24 billion in revenue each year. The company earns $9.94 billion in net income (profit) each year or $17.84 on an earnings per share basis.

How many employees does BioNTech have?

The company employs 4,530 workers across the globe.

Does BioNTech have any subsidiaries?
The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.
Read More
How can I contact BioNTech?

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The official website for the company is www.biontech.de. The company can be reached via phone at 49-61-31908-40, via email at investors@biontech.de, or via fax at 49-6131-908-4390.

This page (NASDAQ:BNTX) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -